Skip to main content

Eltrombopag (Revolade) tablet Online| Blueberry pharmaceuticals

ELTROMBOPAG

Eltrombopag drug may be needed as part of combination therapy. Thereby drug may need to take it with other medications. Eltrombopag is a prescription drug which is used under the guidance of the doctor

INDICATION

Eltrombopag is mainly indicated for the treatment of patients having Reduced platelet levels due to chronic immune thrombocytopenia
Eltrombopag is mainly indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection Eltrombopag is mainly indicated for the treatment of patients having Severe Aplastic Anemia

1. First line treatment of severe Aplastic Anemia
2. Treatment of refractory severe Aplastic Anemia

MECHANISM OF ACTION

Eltrombopag exist in a class of drugs called thrombopoietin (TPO) receptor agonists. Classification of drugs is an association of medications which work in a similar way. These drugs are often used to treat similar conditions.

DOSAGE AND ADMINISTRATION

Chronic Hepatitis C-associated Thrombocytopenia:
The recommended dose: 25 mg PO qDay
The dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pelt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
Severe Aplastic Anemia

COMMON SIDE EFFECTS

nausea
fever
weakness
pain in head
cough
decreased appetite
flu
low red blood cells
diarrhea

PRECAUTIONS

If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse. Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increase the risk of death. If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.

DRUG-DRUG INTERACTION

These drug sezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan interaction with Eltrombopag will increase of side effects. hence the doctor may reduce your dosage of these drugs if required.

PREGNANCY

Pregnancy category is C
Animal studies reveal risk and human studies not available or neither animal nor human studies done.Use the Eltrombopag with caution if asset outweigh risks

LACTATION

The drug is not recommended during breastfeeding.

STORAGE

Store at room temperature 20°C and 25°C Discard the left-out medicine if not used within 30 minutes.

MISSED DOSE

In the case of the missed dose, patients must consult with the medical practitioner and follow the instructions given by them. thereby missed dose should be avoided and follow the regular dosing schedule.

FOR MORE INFORMATION:

EMAIL:

info@blueberrypharma.com

PHONE:

+91-97890 77748

VISIT US:

blueberrypharma.com/eltrombopag.php

Comments

Popular posts from this blog

Cabozantinib tablets online | Blueberry Pharmaceuticals

CABOZANTINIB It belongs to the targeted therapy drug used to cure medullary thyroid cancer and kidney cancer that has spread. Cabozantinib label includes a black box warning of gastrointestinal perforations, fistulas, and haemorrhage. Cabozantinib is a prescription drug which is used under the supervision of doctors
INDICATIONCabozantinib is indicated for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have to get before anti-angiogenic therapy.
MECHANISM OF ACTIONCabozantinib belongs to a type of targeted therapy drug known as a tyrosine kinase inhibitor. It acts by inhibiting the signals inner cancer cells which made them grow and divide. This may help to block or reduced the growth of cancer. It can also prohibit new blood vessels growing in cancer. Cancer cells require to make new blood vessels so they can develop and spread.
DOSAGE AND ADMINISTRATION The prescribed dose of Cabozantinib is 60 mg…

Everotas 5 mg | Everolimus | Blueberry pharmaceuticals

DESCRIPTIONEverotas 5mg belongs to the anti-neoplastic agent; it comes under mTOR kinase inhibitor (single transduction inhibitor). Everotas 5mg is an immunosuppressive macrolide.
USED FORBreast cancer 
The patient who fails to respond to the tablet letrozole or anastrozole therapy would be treated with Everotas. Everotas 5mg is used in an advanced stage of breast cancer.

Neuroendocrine tumors 
Everotas 5mg involved in the treatment of some neuroendocrine tumors like pancreatic, gastrointestinal or lung cancer.

Renal cell cancer 
Patient treating with Everotas 5mg after the failure of treatment with Sunitinib or Sorafenib.
Everotas 5mg also used in the condition of; Heart, liver, kidney transplantation
Waldenström macroglobulinemia
Other carcinoid tumors.
MECHANISM OF ACTION Everotas is the prohibition of mammalian target of rapamycin (mTOR), a serine-threonine kinase.
Everotas bind with intercellular protein (FKBP-12), leads to inhibitory complex formation with mTOR complex 1 (mTORC1) …